ALLANTOINA ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
36Epidermolysis bullosa1

36. Epidermolysis bullosa


Clinical trials : 160 Drugs : 195 - (DrugBank : 47) / Drug target genes : 50 - Drug target pathways : 124
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-005679-96-IT
(EUCTR)
21/01/2021An Investigation into the Long-term Safety of Zorblisa (SD-101-6.0) creamused by Patients with Epidermolysis Bullosa.An Open Label Multi-Center Extension Study to Evaluate the Long-term Safety of ZorblisaTM (SD-101-6.0) in Patients with Epidermolysis Bullosa - Long-term Safety study of Zorblisa in Patients with Epidermolysis Bullosa Epidermolysis Bullosa
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
INN or Proposed INN: ALLANTOINASCIODERM, INCNULLNot RecruitingFemale: yes
Male: yes
150Phase 3Israel;Serbia;United States;Spain;Lithuania;Austria;Netherlands;Germany;Bulgaria;Australia;Romania;Poland;Belgium;France;Italy;United Kingdom